Reported about 8 hours ago
This article discusses two pharmaceutical stocks, Pfizer and Merck, which are currently undervalued despite facing challenges. Pfizer, having generated significant revenue during the pandemic, is now focusing on cost reduction and reinvestment in R&D, while Merck is navigating a patent expiry for its key cancer drug, Keytruda. Both companies are investing in their pipelines and present potential growth opportunities for investors looking for good value in the pharma sector.
Source: YAHOO